Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Outlines Systems Manufacturers Should Have In Place For Handling Suspect Drugs Under DSCSA

Executive Summary

Manufacturers need to have robust verification processes in place and actively communicate with their trading partners to handle suspect drugs that are not properly serialized under DSCA, FDA draft guidance document says.

You may also be interested in...

The Quality Lowdown: DSCSA, Recalls, Extractables & Leachables And Nitrosamines

The US FDA refines guidance on verification systems for suspect drug products and voluntary recalls, while industry groups issue guidance on extractables and leachables in parenteral drugs and the role of excipients in nitrosamine formation.

Industry Groups Seek More Options In Responding To DSCSA Verification Requests

PhRMA and AAM suggest the US FDA should give pharmaceutical manufacturers more time to respond to requests from trading partners to verify that suspect and illegitimate products had been received. They point out that while DSCSA requires responses to verification requests be made within 24 hours, the law allows FDA to make exceptions.

Pharmaceutical Manufacturers Testing Use of Verification Router Services To Process Saleable Returns Under DSCSA

Pharmaceutical manufacturers, distributors and wholesalers are piloting the use of verification router service (VRS) systems to comply with a looming deadline under DSCSA requiring them to establish systems for verifying saleable returns. Yet there are still many unanswered questions on how these systems will work.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts